| Jeremy Larvadain Mckay, MD, MTS | |
|
17 Lansing St, Auburn, NY 13021 | |
| (315) 255-7011 | |
| Not Available |
| Full Name | Jeremy Larvadain Mckay |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 15 Years |
| Location | 17 Lansing St, Auburn, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922237544 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 270031 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Auburn Community Hospital | Auburn, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Auburn Medical Pc | 4789780891 | 15 |
News Archive
Akorn, Inc. today announced that it failed to reach an amicable resolution to a longer term and strategic business arrangement with the supplier of its Tetanus Diphtheria ("Td") vaccine and as a result will be exiting the business. The existing supply agreement will end on March 14, 2010. The company previously announced its intent to exit the distribution of flu vaccines.
Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus. They published their work in Science this week.
Amphora Discovery Corporation, a small molecule drug discovery company, announced today that it has entered into an agreement with Genentech, Inc. pursuant to which Genentech will purchase Amphora's entire program for an unnamed oncology target with the potential to treat multiple oncology indications.
The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules.
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
› Verified 6 days ago
| Entity Name | Auburn Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093712911 PECOS PAC ID: 2365346525 Enrollment ID: O20031120000617 |
News Archive
Akorn, Inc. today announced that it failed to reach an amicable resolution to a longer term and strategic business arrangement with the supplier of its Tetanus Diphtheria ("Td") vaccine and as a result will be exiting the business. The existing supply agreement will end on March 14, 2010. The company previously announced its intent to exit the distribution of flu vaccines.
Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus. They published their work in Science this week.
Amphora Discovery Corporation, a small molecule drug discovery company, announced today that it has entered into an agreement with Genentech, Inc. pursuant to which Genentech will purchase Amphora's entire program for an unnamed oncology target with the potential to treat multiple oncology indications.
The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules.
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
› Verified 6 days ago
| Entity Name | Upstate Medical Anesthesiology Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851485759 PECOS PAC ID: 8921992389 Enrollment ID: O20040209000612 |
News Archive
Akorn, Inc. today announced that it failed to reach an amicable resolution to a longer term and strategic business arrangement with the supplier of its Tetanus Diphtheria ("Td") vaccine and as a result will be exiting the business. The existing supply agreement will end on March 14, 2010. The company previously announced its intent to exit the distribution of flu vaccines.
Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus. They published their work in Science this week.
Amphora Discovery Corporation, a small molecule drug discovery company, announced today that it has entered into an agreement with Genentech, Inc. pursuant to which Genentech will purchase Amphora's entire program for an unnamed oncology target with the potential to treat multiple oncology indications.
The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules.
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
› Verified 6 days ago
| Entity Name | Gastroenterology & Hepatology Of Central New York, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043202641 PECOS PAC ID: 3072505411 Enrollment ID: O20040402001028 |
News Archive
Akorn, Inc. today announced that it failed to reach an amicable resolution to a longer term and strategic business arrangement with the supplier of its Tetanus Diphtheria ("Td") vaccine and as a result will be exiting the business. The existing supply agreement will end on March 14, 2010. The company previously announced its intent to exit the distribution of flu vaccines.
Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus. They published their work in Science this week.
Amphora Discovery Corporation, a small molecule drug discovery company, announced today that it has entered into an agreement with Genentech, Inc. pursuant to which Genentech will purchase Amphora's entire program for an unnamed oncology target with the potential to treat multiple oncology indications.
The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules.
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
› Verified 6 days ago
| Entity Name | Auburn Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861590432 PECOS PAC ID: 4789780891 Enrollment ID: O20070507000505 |
News Archive
Akorn, Inc. today announced that it failed to reach an amicable resolution to a longer term and strategic business arrangement with the supplier of its Tetanus Diphtheria ("Td") vaccine and as a result will be exiting the business. The existing supply agreement will end on March 14, 2010. The company previously announced its intent to exit the distribution of flu vaccines.
Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus. They published their work in Science this week.
Amphora Discovery Corporation, a small molecule drug discovery company, announced today that it has entered into an agreement with Genentech, Inc. pursuant to which Genentech will purchase Amphora's entire program for an unnamed oncology target with the potential to treat multiple oncology indications.
The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules.
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeremy Larvadain Mckay, MD, MTS 17 Lansing St, Auburn, NY 13021-1983 Ph: (315) 255-7011 | Jeremy Larvadain Mckay, MD, MTS 17 Lansing St, Auburn, NY 13021 Ph: (315) 255-7011 |
News Archive
Akorn, Inc. today announced that it failed to reach an amicable resolution to a longer term and strategic business arrangement with the supplier of its Tetanus Diphtheria ("Td") vaccine and as a result will be exiting the business. The existing supply agreement will end on March 14, 2010. The company previously announced its intent to exit the distribution of flu vaccines.
Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus. They published their work in Science this week.
Amphora Discovery Corporation, a small molecule drug discovery company, announced today that it has entered into an agreement with Genentech, Inc. pursuant to which Genentech will purchase Amphora's entire program for an unnamed oncology target with the potential to treat multiple oncology indications.
The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules.
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
› Verified 6 days ago
Gregory A Garnes, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 17 Lansing St, Auburn, NY 13021 Phone: 315-255-7011 | |
David Marker, CRNA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 17 Lansing St, Auburn, NY 13021 Phone: 315-255-7220 | |
Dr. Xi Yang, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 17 Lansing St, Auburn, NY 13021 Phone: 315-255-7011 | |
Gary H Wishik, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 17 Lansing St, Auburn, NY 13021 Phone: 315-255-7204 | |
Dr. Jason Lok, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 17 Lansing St, Auburn, NY 13021 Phone: 315-255-7011 Fax: 315-255-7099 |